Examkin

Soru

Zorluk: Çok zorPharmacologic Interventions

A 7171-year-old female presents to the cardiology clinic for an urgent consultation regarding worsening shortness of breath and ankle swelling over the past 66 weeks. She reports needing three pillows to sleep at night and becomes breathless after walking just one block. Her past medical history is notable for seropositive rheumatoid arthritis, type 2 diabetes mellitus, essential hypertension, and stage 4 chronic kidney disease. Her medication regimen includes oral methotrexate, subcutaneous adalimumab, metformin, sitagliptin, and lisinopril.

Vital signs show a blood pressure of 134/82 mmHg134/82 \text{ mmHg} and a heart rate of 88 /min88\text{ /min}. Physical examination reveals distended jugular veins, crackles in the lower third of both lung fields, and bilateral 2+2+ pitting edema up to the mid-calves.

A transthoracic echocardiogram reveals global hypokinesis with an estimated left ventricular ejection fraction of 25%25\%.

Current laboratory values:
Serum potassium: 4.6 mEq/L4.6 \text{ mEq/L}
Serum creatinine: 2.5 mg/dL2.5 \text{ mg/dL} (estimated GFR: 22 mL/min/1.73 m222 \text{ mL/min/}1.73 \text{ m}^2; baseline 33 months ago: 2.4 mg/dL2.4 \text{ mg/dL})
Hemoglobin A1c: 7.2%7.2\%

Which of the following sets of modifications to this patient's current medications is most appropriate?

  1. A
    Discontinuation of adalimumab and substitution of sitagliptin with pioglitazone
  2. B
    Discontinuation of methotrexate and initiation of infliximab
  3. Discontinuation of adalimumab and metforminCevap
  4. D
    Discontinuation of lisinopril and immediate initiation of sacubitril-valsartan
  5. E
    Discontinuation of lisinopril and metformin

Cevap

The most appropriate modification is the discontinuation of both adalimumab and metformin.
The correct action addresses the two most critical and absolute pharmacologic contraindications in this patient's presentation. First, adalimumab is a TNF-alpha inhibitor. The use of TNF-alpha inhibitors in patients with New York Heart Association (NYHA) class III or IV heart failure is contraindicated because they have been shown to exacerbate heart failure and increase mortality. Second, the patient's estimated GFR has declined to 22 mL/min/1.73 m². Metformin is absolutely contraindicated in patients with an eGFR < 30 mL/min/1.73 m² due to an unacceptably high risk of developing metformin-associated lactic acidosis. Both medications must be stopped immediately.

Adım Adım Çözüm

1
Identify the patient's new acute clinical syndrome and synthesize it with her chronic conditions.
The patient has new-onset heart failure with reduced ejection fraction (HFrEF) presenting as NYHA Class III symptoms (LVEF 25%, orthopnea, edema). She also has Stage 4 chronic kidney disease (CKD) with an eGFR of 22 mL/min/1.73 m².
Accurate identification of the intersection of new diagnoses with underlying chronic organ dysfunction is required before evaluating pharmacologic safety.
2
Evaluate the patient's current rheumatoid arthritis therapy (adalimumab, methotrexate) against the new HFrEF diagnosis.
Adalimumab must be discontinued.
Tumor necrosis factor (TNF)-alpha inhibitors are known to worsen heart failure and are absolutely contraindicated in patients with moderate to severe (NYHA class III or IV) heart failure.
3
Evaluate the patient's current diabetes therapy (metformin, sitagliptin) against her current renal function.
Metformin must be discontinued.
Metformin carries a black box warning for lactic acidosis in severe renal impairment and is contraindicated when the eGFR falls below 30 mL/min/1.73 m².
4
Evaluate the safety of continuing the ACE inhibitor (lisinopril) given her elevated creatinine.
Lisinopril should be continued.
The patient's creatinine of 2.5 mg/dL is stable compared to her baseline of 2.4 mg/dL, and her potassium is normal (4.6 mEq/L). ACE inhibitors provide a significant mortality benefit in HFrEF and should not be stopped for stable CKD.

Anahtar Kavram

Polypharmacy management requires routine reassessment for contraindications, specifically avoiding TNF-alpha inhibitors in severe heart failure, avoiding metformin in severe chronic kidney disease (eGFR < 30), and ensuring proper washout periods between ACE inhibitors and ARNIs.
Tahmini Süre:2m 0s
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru